Highlights • Allogeneic cell therapy holds promise as off-the-shelf cancer immunotherapy • Tumor and viral escape mechanisms provide blueprints for engineering immune-evasive states • Deletion of CD54 and CD58 in donor immune cells reduces their rejection by host immunity • Unidirectional synapse manipulation ensures maintained antitumor functionality Summary Allogeneic cellular immunotherapies hold promise for broad clinical implementation but face limitations due to potential rejection of...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Quirin
Contact Quirin, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack